Net product sales consist of the following: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended
June 30, | | Six Months Ended
June 30, | | (In millions) | | | | 2026 | | 2025 | | 2026 | | 2025 | EYLEA HD® | | U.S. | | $ | 596.3 | | | $ | 393.2 | | | $ | 1,064.7 | | | $ | 700.0 | | EYLEA® | | U.S. | | 412.2 | | | 754.3 | | | 885.3 | | | 1,490.3 | | | Total EYLEA HD and EYLEA | | U.S. | | 1,008.5 | | | 1,147.5 | | | 1,950.0 | | | 2,190.3 | | Libtayo® | | U.S. | | 342.6 | | | 247.8 | | | 628.7 | | | 440.3 | | Libtayo | | Rest of world | | 146.8 | | | 128.7 | | | 298.9 | | | 221.3 | | Total Libtayo | | Global | | 489.4 | | | 376.5 | | | 927.6 | | | 661.6 | | Praluent® | | U.S. | | 74.7 | | | 65.8 | | | 141.3 | | | 122.6 | | Evkeeza® | | U.S. | | 53.3 | | | 41.2 | | | 99.0 | | | 72.1 | | Lynozyfic® | | Global | | 16.5 | | | — | | | 27.7 | | | — | | Other products | | Global | | — | | | — | | | 31.3 | | | — | | | | | | $ | 1,642.4 | | | $ | 1,631.0 | | | $ | 3,176.9 | | | $ | 3,046.6 | |
Amounts recognized in the Company's Statements of Operations in connection with its Sanofi collaboration are as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Statement of Operations Classification | | Three Months Ended
June 30, | | Six Months Ended
June 30, | | (In millions) | | | 2026 | | 2025 | | 2026 | | 2025 | Regeneron's share of profits | | Collaboration revenue | | $ | 2,032.6 | | | $ | 1,282.1 | | | $ | 3,483.4 | | | $ | 2,300.2 | | | Reimbursement for manufacturing of commercial supplies | | Collaboration revenue | | $ | 141.7 | | | $ | 161.5 | | | $ | 296.0 | | | $ | 326.6 | | | Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses | | (R&D expense) | | $ | (19.4) | | | $ | (18.0) | | | $ | (36.1) | | | $ | (33.5) | | Reimbursement of commercialization-related expenses | | Reduction of SG&A expense | | $ | 188.8 | | | $ | 194.0 | | | $ | 372.9 | | | $ | 353.2 | |
Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Statement of Operations Classification | | Three Months Ended
June 30, | | Six Months Ended
June 30, | | (In millions) | | | 2026 | | 2025 | | 2026 | | 2025 | Regeneron's share of profits | | Collaboration revenue | | $ | 227.3 | | | $ | 383.4 | | | $ | 467.3 | | | $ | 700.7 | | Reimbursement for manufacturing of commercial supplies | | Collaboration revenue | | $ | 48.9 | | | $ | 31.6 | | | $ | 96.2 | | | $ | 58.2 | | | Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses | | (R&D expense)/Reduction of R&D expense | | $ | (0.6) | | | $ | (5.6) | | | $ | 0.4 | | | $ | (15.0) | |
|